Archive Newsletter

41. 04.24.26 -- U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/24/2026
    04/24/26 Cell & Gene Newsletter
42. 04.23.26 -- Mastering Biotech's Insourcing/Outsourcing Trade-Offs 4/23/2026
    04/23/26 Cell & Gene Newsletter
43. 04.22.26 -- Building Resilient Biomanufacturing From Media To Market 4/22/2026

    04/22/26 Cell & Gene Newsletter

44. 04.22.26 -- From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations 4/22/2026
    04/22/26 Cell & Gene Newsletter
45. 04.21.26 -- All The Ways Global Biopharma Still Grapples With Annex 1 4/21/2026
    04/21/26
46. 04.21.26 -- STREAM Edition: Bridging Analytical Gaps To Ensure CGT Material Quality 4/21/2026

    04/21/26 Cell & Gene Newsletter

47. 04.20.26 -- Why A Cell Therapy CEO Waited Until Phase III To Outsource 4/20/2026
    04/20/26 Cell & Gene Newsletter
48. 04.17.26 -- Large Molecule Capacity Powering Cell & Gene Therapies 4/17/2026

    04/17/26 Cell & Gene Newsletter

49. 04.17.26 -- Building Smarter Cell Therapies With AI And Synthetic Biology 4/17/2026
    04/17/26 Cell & Gene Newsletter
50. 04.16.26 -- Cell & Gene Capabilities That You Need to Know 4/16/2026

    04/16/26 Cell & Gene Newsletter